[Combined Efficacy of Dendritic Cell Vaccine and Oncolytic Adenovirus in Colorectal Cancer].
Dendritic cell(DC)vaccine therapy has been widely studied as cancer immunotherapy that potently induces cytotoxic T lymphocytes. However, their efficacy in clinical practice has not yet been established. We have developed an oncolytic adenovirus OBP-702 carrying the tumor suppressor gene p53 and have demonstrated its therapeutic potential to induce cytopathic effect and activate antitumor immunity via p53 induction. In this study, we investigated the combined effect of p53-transduced DC vaccine and OBP-702 in colorectal cancer.
Authors
- Hiroshi Tazawa (ORCID: https://orcid.org/0000-0003-4658-1050)
- Kanto Suemori
- Shinji Kuroda (ORCID: https://orcid.org/0000-0003-3100-8243)
- Satoru Kikuchi (ORCID: https://orcid.org/0000-0002-7671-0696)
- Shunsuke Kagawa (ORCID: https://orcid.org/0000-0002-3610-8211)
- Toshiyoshi Fujiwara (ORCID: https://orcid.org/0000-0002-5377-6051)
- Kazuhiro Noma (ORCID: https://orcid.org/0000-0002-5584-3908)
- Motohiko Yamada (ORCID: https://orcid.org/0000-0003-3451-335X)
- Naohiro Okada
- Yasuo Urata
Institutions
- Okayama University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- Primary Topic
- Virus-based gene therapy research
- Type
- article